Clinical Trial Update: A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of MT-2111 in relapsed or refractory Diffuse Large B-Cell Lymphoma is ongoing, with the trial status shown as active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• MT-2111

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Diffuse Large B-Cell Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING